Droplet Digital PCR (ddPCR) enables easy multiplexing of numerous targets within each fluorescent channel. Amplitude-based multiplexing achieves this by varying primer and/or probe concentrations. In probe-mixing multiplexing, probes are mixed at desired concentrations to place targets in a defined position on a 2-D plot. This paper describes strategies for both approaches using the large portfolio of ddPCR assays.
At the Fred Hutchinson Cancer Research Center in Seattle, scientists are producing some of the most important advances in prevention, early detection and treatment of cancer and other diseases. This case study discusses how Droplet Digital PCR is being used to break through the current limits of nucleic acid detection and quantification.
By using cell-free DNA (cfDNA) to quantify cancer markers in blood or other bodily fluids, liquid biopsies can eliminate the need for invasive surgical procedures. Droplet Digital PCR has enabled absolute and highly sensitive nucleic acid quantification that is less susceptible to PCR inhibition than RT-qPCR and less costly and complicated than NGS workflows.
Chronic myelogenous leukemia (CML) is a cancer of myeloid cells that accounts for 15 percent to 20 percent of all cases of leukemia. Most CML cases are caused by a translocation between chromosomes 9 and 22 that creates an abnormal fusion gene, BCR-ABL1. This poster explains how Bio-Rad’s QXDx™ BCR-ABL %IS Kit quantifies the amount of BCR-ABL1 transcript as a ratio of BCR-ABL1/ABL1, then returns the value of Molecular Response (MR) and on the WHO International Scale (IS).
Through the use of liquid biopsy with Droplet Digital PCR (ddPCR), clinical laboratories can now support clinicians in determining the most effective treatment based on a patient’s oncogenomic profile.